Therapy Areas: Central Nervous System
TRIMTECH Therapeutics partners with Biogen to develop protein degraders for neurodegenerative diseases
16 November 2026 -

UK biotechnology company TRIMTECH Therapeutics announced on Monday that it has entered into a strategic research collaboration, option and licence agreement with Biogen International GmbH, part of US biotechnology company Biogen Inc (NASDAQ:BIIB), to develop small molecule protein degraders targeting neurodegenerative diseases.

The collaboration will leverage TRIMTECH's proprietary TRIM21-based targeted protein degradation technology to discover and develop therapies targeting toxic protein aggregates associated with neurodegenerative conditions.

Under the agreement, TRIMTECH is eligible to receive up to USD32m in upfront and research milestone payments, with total potential payments of up to USD411m, plus royalties. If Biogen exercises its option, it will receive a global exclusive licence to the resulting degraders and assume responsibility for further development and commercialisation.

TRIMTECH's technology uses small molecule TRIMTAC and TRIMGLUE degraders designed to access the central nervous system and selectively break down toxic protein aggregates and oligomers implicated in neurodegenerative diseases.

Login
Username:

Password: